Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO and managing director Nina Webster chats with Proactive live from the ASX Small and Mid Cap Conference in March 2024. The clinical stage biopharma is developing a scalable, proprietary platform technology called Receptor-HIT, the backbone of a novel treatment known as DMX-200.
Webster says the treatment candidate has the potential to transform the lives of patients with inflammatory diseases, such as kidney or lung disease, and is backed up by a team with considerable experience in the commercialisatiion and development of pharmaceuticals.